Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuronopathy, Distal Hereditary Motor, Type IIB 1Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × apatorsen × Clear all
NCT00487786 2016-01-18

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Achieve Life Sciences

Phase 1 Completed
64 enrolled
Tumor-Agnostic

Neoplasms

NCT00959868 2012-02-13

A Study for Treatment of Superficial Bladder Cancer Using OGX-427

Vancouver Coastal Health

Phase 1 Unknown
36 enrolled
Genitourinary

Neuronopathy, Distal Hereditary Motor, Type IIB, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡